MARKET

ZYME

ZYME

Zymeworks
NASDAQ
22.88
-0.09
-0.37%
After Hours: 22.70 -0.18 -0.79% 16:59 06/12 EDT
OPEN
23.02
PREV CLOSE
22.97
HIGH
23.46
LOW
22.76
VOLUME
522.96K
TURNOVER
--
52 WEEK HIGH
29.75
52 WEEK LOW
11.51
MARKET CAP
1.67B
P/E (TTM)
-16.7349
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO) and Zymeworks (ZYME)
TipRanks · 4d ago
Zymeworks assumed with a Buy at Truist
TipRanks · 4d ago
ZYMEWORKS INC <ZYME.O>: TRUIST SECURITIES CUTS TARGET PRICE TO $28 FROM $40
Reuters · 4d ago
Weekly Report: what happened at ZYME last week (0601-0605)?
Weekly Report · 5d ago
A Look At Zymeworks (ZYME) Valuation After Recent Clinical And Regulatory Milestones
Simply Wall St · 6d ago
Is Zymeworks’ ADC Progress And Buyback Plan Reframing The Investment Case For ZYME?
Simply Wall St · 06/05 18:23
Zymeworks and BeOne: Long‑Term Cancer Study Update Supports Durable Drug Story
TipRanks · 06/03 16:31
Analyst Reaffirms Buy on Ziihera’s HER2+ GEA Strength, Maintains $46 Price Target Ahead of 2026 PDUFA
TipRanks · 06/03 11:25
More
About ZYME
Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.

Webull offers Zymeworks Inc stock information, including NASDAQ: ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZYME stock methods without spending real money on the virtual paper trading platform.